Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImmuRAID-CEA antibody fragment labelled with technetium-99m data

Results of a Phase II trial show that in 33 percent of the 54 patients enrolled,

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE